- Nurix Therapeutics (NRIX, Financial) presented promising preclinical data at AACR 2025, showcasing several brain-penetrant degraders targeting notable oncology targets.
- The lead BTK degrader, bexobrutideg, exhibited remarkable efficiency, degrading approximately 10,000 BTK copies per hour.
- NRX-0305 demonstrated substantial anti-tumor efficacy in resistant tumors, while NRX-4972 showed significant potential in neuroblastoma models.
Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company, shared positive preclinical findings at the American Association for Cancer Research (AACR) 2025 Annual Meeting. The presentations underscored the potential of their protein degraders, designed to target brain-penetrant oncology applications.
Bexobrutideg, their leading BTK degrader, showcased an extraordinary ability to degrade approximately 10,000 BTK copies per hour at clinically relevant concentrations. This highlights the drug's catalytic efficiency, suggesting potential efficacy at lower concentrations compared to traditional inhibitors.
Additionally, Nurix presented data on NRX-0305, a BRAF degrader which targets all three classes of BRAF mutations, sparing healthy cells and exhibiting superior anti-tumor activity in resistant tumors compared to competitor drug CFT1946. This degrader showed effectiveness in combination with MEKi, enhancing its therapeutic potential.
Nurix also revealed promising results for NRX-4972, an Aurora A kinase degrader developed through collaboration with Alex's Lemonade Stand Foundation. This degrader demonstrated significant efficacy in neuroblastoma models, effectively inducing DNA damage, apoptosis, and G2/M arrest, thereby outperforming traditional inhibitors.
